Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Incyte Corporation (INCY) vs LYFT Inc (LYFT) Price & Performance

Incyte CorporationTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs LYFT Inc — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.65B), while LYFT Inc trades at $17.48 (market cap $6.53B). The key difference: Incyte Corporation is far larger — about 3.8× LYFT Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals.

INCYLYFT
Market Cap
$24.65B$6.53B
Sector
HealthIndustrials
52-Week High
$129.93$24.57
52-Week Low
$81.61$12.65
Enterprise Value
$20.15B$6.00B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Incyte Corporation

Incyte Corporation (INCY) trades at $120.56, up 1.84% on the day, near its 52-week high of $120.70. The stock shows a bullish technical trend with strong earnings beats in Q1 and Q2 2026, including Q2 EPS of $3.09 versus $2.15 expected. Revenue growth accelerated to $5.14 billion in 2025, with a net income margin of 27.71%. Recent news highlights EU approval for Opzelura and a raised 2026 revenue outlook, fueling positive momentum.

The outlook remains favorable with analyst consensus at Buy and a $122.82 price target, though risks include reliance on key drugs like Jakafi and competitive pressures. Earnings growth and pipeline advancements support upside, but investors should monitor execution against guidance and regulatory developments.

LYFT Inc

Lyft trades at $17.46, up 7.12% in the past 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong revenue growth to $6.32 billion in 2025 and a net income of $2.84 billion, though recent Q2 2026 earnings missed estimates. Positive cash flow trends and record active riders above 30 million signal operational strength, while an ongoing legal investigation presents a headwind.

The outlook is mixed: valuation ratios like P/E of 2.54 appear attractive, and analyst consensus targets $19.17, but earnings misses and competitive pressures weigh on sentiment. Key risks include fiduciary duty investigations and moderating booking growth, requiring careful monitoring of execution against guidance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY

About LYFT Inc

Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.

Read more on LYFT